214 related articles for article (PubMed ID: 27571366)
1. The evolution and outcome of surveillance of Barrett's oesophagus over four decades in a UK District General Hospital.
Royston C; Caygill C; Charlett A; Bardhan KD
Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1365-1373. PubMed ID: 27571366
[TBL] [Abstract][Full Text] [Related]
2. Adam, Eve and the reflux enigma: age and sex differences across the gastro-oesophageal reflux spectrum.
Royston C; Bardhan KD
Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):634-639. PubMed ID: 28151751
[TBL] [Abstract][Full Text] [Related]
3. Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study.
Alexandropoulou K; van Vlymen J; Reid F; Poullis A; Kang JY
Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):15-21. PubMed ID: 23022985
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and prevention of oesophageal adenocarcinoma.
Ness-Jensen E
Scand J Gastroenterol; 2022 Aug; 57(8):891-895. PubMed ID: 35234549
[TBL] [Abstract][Full Text] [Related]
5. The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off.
Masclee GM; Coloma PM; de Wilde M; Kuipers EJ; Sturkenboom MC
Aliment Pharmacol Ther; 2014 Jun; 39(11):1321-30. PubMed ID: 24738722
[TBL] [Abstract][Full Text] [Related]
6. Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus.
Holmberg D; Ness-Jensen E; Mattsson F; El-Serag HB; Lagergren J
Eur J Cancer; 2017 Apr; 75():41-46. PubMed ID: 28214656
[TBL] [Abstract][Full Text] [Related]
7. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
8. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
[TBL] [Abstract][Full Text] [Related]
9. Barrett's oesophagus: an audit of surveillance over a 17-year period.
Gladman L; Chapman W; Iqbal TH; Gearty JC; Cooper BT
Eur J Gastroenterol Hepatol; 2006 Mar; 18(3):271-6. PubMed ID: 16462540
[TBL] [Abstract][Full Text] [Related]
10. Adenocarcinoma risk in patients registered with Polish Barrett's Oesophagus Registry.
Januszewicz W; Kaminski MF; Wieszczy P; Wronska E; Bielasik A; Wojciechowska U; Didkowska J; Orlowska J; Regula J
Dis Esophagus; 2017 Jan; 30(1):1-6. PubMed ID: 27377059
[TBL] [Abstract][Full Text] [Related]
11. Review article: Barrett's oesophagus and associated adenocarcinoma--a UK perspective.
Fitzgerald RC
Aliment Pharmacol Ther; 2004 Dec; 20 Suppl 8():45-9. PubMed ID: 15575873
[TBL] [Abstract][Full Text] [Related]
12. Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis.
Eusebi LH; Cirota GG; Zagari RM; Ford AC
Gut; 2021 Mar; 70(3):456-463. PubMed ID: 32732370
[TBL] [Abstract][Full Text] [Related]
13. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.
Kastelein F; van Olphen SH; Steyerberg EW; Spaander MC; Bruno MJ;
Gut; 2016 Apr; 65(4):548-54. PubMed ID: 25903690
[TBL] [Abstract][Full Text] [Related]
14. Review article: Barrett's oesophagus and carcinoma in Japan.
Hongo M
Aliment Pharmacol Ther; 2004 Dec; 20 Suppl 8():50-4. PubMed ID: 15575874
[TBL] [Abstract][Full Text] [Related]
15. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis.
Singh S; Garg SK; Singh PP; Iyer PG; El-Serag HB
Gut; 2014 Aug; 63(8):1229-37. PubMed ID: 24221456
[TBL] [Abstract][Full Text] [Related]
16. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis.
Desai TK; Krishnan K; Samala N; Singh J; Cluley J; Perla S; Howden CW
Gut; 2012 Jul; 61(7):970-6. PubMed ID: 21997553
[TBL] [Abstract][Full Text] [Related]
17. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
[TBL] [Abstract][Full Text] [Related]
18. Rising incidence of clinically evident Barrett's oesophagus in The Netherlands: a nation-wide registry of pathology reports.
Post PN; Siersema PD; Van Dekken H
Scand J Gastroenterol; 2007 Jan; 42(1):17-22. PubMed ID: 17190757
[TBL] [Abstract][Full Text] [Related]
19. [Barrett's oesophagus: endoscopic diagnosis and follow-up].
Ponsot P
Ann Chir; 2006 Jan; 131(1):3-6. PubMed ID: 16376849
[TBL] [Abstract][Full Text] [Related]
20. The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma.
den Hoed CM; van Blankenstein M; Dees J; Kuipers EJ
Br J Cancer; 2011 Jul; 105(2):200-5. PubMed ID: 21673678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
